MYX 3.56% $4.60 mayne pharma group limited

Ann: FDA Approval Of New Dual-Scored 150mg Doryx , page-6

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,181 Posts.
    lightbulb Created with Sketch. 12
    re: Ann: FDA Approval Of New Dual-Scored 150m... I agree, this is a great company with good products (I have been watching this since Halcygen acquired Mayne Pharma which was a great buy and it is nice to see their other products are increasing sales so hopefully MYX is less reliant on Doryx).

    However the uncertainty with SUBACAP (see SUBACAP update announcement 15/12/11) being delayed past 30/6/12 due to further questions by the UK MHRA has IMO caused the SP to weaken (it rose to over 50c before the fall I think in the belief that SUBACAP news would be good).

    Hopefully the news from FDA in regards to Phase III is more positive.
 
watchlist Created with Sketch. Add MYX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.